ID   Shef-MFS 01 w2 variant
AC   CVCL_C8VH
SY   Shef-MFS01 w2; STS 21/11 w2; Sheffield Myxofibrosarcoma Cell Line 01 (w2 variant)
DR   Wikidata; Q123033486
RX   PubMed=27560552;
WW   Provider; UOS; -; https://licensing.sheffield.ac.uk/product/sarcoma-cell-lines
CC   Doubling time: 56.30 hours (Note=At 31th passage) (PubMed=27560552).
CC   Omics: Variations; Array-based CGH.
CC   Derived from site: In situ; Arm, hypodermis; UBERON=UBERON_0001460+UBERON_0002072.
ST   Source(s): PubMed=27560552
ST   Amelogenin: X,Y
ST   CSF1PO: 10
ST   D13S317: 13
ST   D16S539: 12
ST   D21S11: 30,31.2
ST   D5S818: 12,13
ST   D7S820: 8,9
ST   TH01: 8
ST   TPOX: 11
ST   vWA: 14,16
DI   NCIt; C6496; Myxofibrosarcoma
DI   ORDO; Orphanet_79105; Myxofibrosarcoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_C8VG ! Shef-MFS 01 w1 variant
SX   Male
AG   73Y
CA   Cancer cell line
DT   Created: 05-10-23; Last updated: 10-04-25; Version: 3
//
RX   PubMed=27560552; DOI=10.1038/bjc.2016.259; PMCID=PMC5117779;
RA   Salawu A., Fernando M., Hughes D., Reed M.W.R., Woll P.J., Greaves C.,
RA   Day C., Alhajimohammed M.A., Sisley K.;
RT   "Establishment and molecular characterisation of seven novel
RT   soft-tissue sarcoma cell lines.";
RL   Br. J. Cancer 115:1058-1068(2016).
//